首页|多发性骨髓瘤细胞来源的细胞外囊泡在临床诊疗中的研究进展

多发性骨髓瘤细胞来源的细胞外囊泡在临床诊疗中的研究进展

扫码查看
多发性骨髓瘤(multiple myeloma,MM)细胞来源的细胞外囊泡(extracellular vesicles,EVs)通过转运特异性生物活性分子进行细胞间通信,参与血管生成、骨溶解、免疫抑制、耐药性等多个过程,因此可以作为有潜力的生物标志物辅助诊断和探索MM治疗的新方式.本文旨在综述其重塑骨髓微环境促进MM进展的机制、与耐药性的关系、作为生物标志物的研究进展、通过作为干扰通信的治疗靶点和工程化改造促进MM治疗的临床前景,分析得出特定MM-EVs的纯化表征、功能分析和安全性是MM-EVs临床转化的重要挑战.
Research progress of multiple myeloma cell-derived extracellular vesicles in clinical diagnosis and treatment
Multiple myeloma cell-derived extracellular vesicles(MM-EVs)are involved in multiple myeloma related processes such as angiogenesis,osteolysis,immune suppression,and drug resistance through intercellular communication by transporting specific bioactive cargo,so they can be used as potential biomarkers to assist in di-agnosis and new therapeutic strategies for multiple myeloma.This review summarizes the mechanism of MM-EVs remodeling the bone marrow microenvironment to promote the progression of multiple myeloma and their relation-ship with drug resistance.Finally,we illustrate their research progress as a biomarker and the clinical prospect of promoting the treatment of multiple myeloma including MM-EVs based therapeutic targets for interference com-munication and engineering modification.The purification and characterization,functional analysis and safety of specific MM-EVs are important challenges for their clinical transformation.

extracellular vesiclesmultiple myelomabone marrow microenvironmentbiomarkers

徐红佩、肖淑梅、王珊、曹玉林、陈智超、李秋柏

展开 >

华中科技大学同济医学院附属协和医院血液病研究所(武汉,430022)

南昌大学第一附属医院

细胞外囊泡 多发性骨髓瘤 骨髓微环境 生物标志物

十四五国家重点研发计划专项项目国家自然科学基金重大研究计划国家自然科学基金面上项目

2021YFA11015009204911981974009

2024

临床血液学杂志
华中科技大学同济医学院血液病研究所 北京医科大学血液病研究所

临床血液学杂志

CSTPCD
影响因子:1.063
ISSN:1004-2806
年,卷(期):2024.37(9)